# Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

> **NCT00439140** · PHASE3 · TERMINATED · sponsor: **Allergan** · enrollment: 41 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **BIOLOGICAL:** botulinum toxin Type A
- **DRUG:** Normal Saline (Placebo)

## Key facts

- **NCT ID:** NCT00439140
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** In agreement with FDA the study was terminated based on data available.
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439140, "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00439140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*